Cargando…
Proteomic research in sarcomas – current status and future opportunities
Sarcomas are a rare group of mesenchymal cancers comprising over 70 different histological subtypes. For the majority of these diseases, the molecular understanding of the basis of their initiation and progression remains unclear. As such, limited clinical progress in prognosis or therapeutic regime...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academic Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083238/ https://www.ncbi.nlm.nih.gov/pubmed/31722230 http://dx.doi.org/10.1016/j.semcancer.2019.11.003 |
_version_ | 1783508495398600704 |
---|---|
author | Burns, Jessica Wilding, Christopher P L Jones, Robin H Huang, Paul |
author_facet | Burns, Jessica Wilding, Christopher P L Jones, Robin H Huang, Paul |
author_sort | Burns, Jessica |
collection | PubMed |
description | Sarcomas are a rare group of mesenchymal cancers comprising over 70 different histological subtypes. For the majority of these diseases, the molecular understanding of the basis of their initiation and progression remains unclear. As such, limited clinical progress in prognosis or therapeutic regimens have been made over the past few decades. Proteomics techniques are being increasingly utilised in the field of sarcoma research. Proteomic research efforts have thus far focused on histological subtype characterisation for the improvement of biological understanding, as well as for the identification of candidate diagnostic, predictive, and prognostic biomarkers for use in clinic. However, the field itself is in its infancy, and none of these proteomic research findings have been translated into the clinic. In this review, we provide a brief overview of the proteomic strategies that have been employed in sarcoma research. We evaluate key proteomic studies concerning several rare and ultra-rare sarcoma subtypes including, gastrointestinal stromal tumours, osteosarcoma, liposarcoma, leiomyosarcoma, malignant rhabdoid tumours, Ewing sarcoma, myxofibrosarcoma, and alveolar soft part sarcoma. Consequently, we illustrate how routine implementation of proteomics within sarcoma research, integration of proteomics with other molecular profiling data, and incorporation of proteomics into clinical trial studies has the potential to propel the biological and clinical understanding of this group of complex rare cancers moving forward. |
format | Online Article Text |
id | pubmed-7083238 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Academic Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-70832382020-04-01 Proteomic research in sarcomas – current status and future opportunities Burns, Jessica Wilding, Christopher P L Jones, Robin H Huang, Paul Semin Cancer Biol Article Sarcomas are a rare group of mesenchymal cancers comprising over 70 different histological subtypes. For the majority of these diseases, the molecular understanding of the basis of their initiation and progression remains unclear. As such, limited clinical progress in prognosis or therapeutic regimens have been made over the past few decades. Proteomics techniques are being increasingly utilised in the field of sarcoma research. Proteomic research efforts have thus far focused on histological subtype characterisation for the improvement of biological understanding, as well as for the identification of candidate diagnostic, predictive, and prognostic biomarkers for use in clinic. However, the field itself is in its infancy, and none of these proteomic research findings have been translated into the clinic. In this review, we provide a brief overview of the proteomic strategies that have been employed in sarcoma research. We evaluate key proteomic studies concerning several rare and ultra-rare sarcoma subtypes including, gastrointestinal stromal tumours, osteosarcoma, liposarcoma, leiomyosarcoma, malignant rhabdoid tumours, Ewing sarcoma, myxofibrosarcoma, and alveolar soft part sarcoma. Consequently, we illustrate how routine implementation of proteomics within sarcoma research, integration of proteomics with other molecular profiling data, and incorporation of proteomics into clinical trial studies has the potential to propel the biological and clinical understanding of this group of complex rare cancers moving forward. Academic Press 2020-04 /pmc/articles/PMC7083238/ /pubmed/31722230 http://dx.doi.org/10.1016/j.semcancer.2019.11.003 Text en © 2019 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Burns, Jessica Wilding, Christopher P L Jones, Robin H Huang, Paul Proteomic research in sarcomas – current status and future opportunities |
title | Proteomic research in sarcomas – current status and future opportunities |
title_full | Proteomic research in sarcomas – current status and future opportunities |
title_fullStr | Proteomic research in sarcomas – current status and future opportunities |
title_full_unstemmed | Proteomic research in sarcomas – current status and future opportunities |
title_short | Proteomic research in sarcomas – current status and future opportunities |
title_sort | proteomic research in sarcomas – current status and future opportunities |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083238/ https://www.ncbi.nlm.nih.gov/pubmed/31722230 http://dx.doi.org/10.1016/j.semcancer.2019.11.003 |
work_keys_str_mv | AT burnsjessica proteomicresearchinsarcomascurrentstatusandfutureopportunities AT wildingchristopherp proteomicresearchinsarcomascurrentstatusandfutureopportunities AT ljonesrobin proteomicresearchinsarcomascurrentstatusandfutureopportunities AT hhuangpaul proteomicresearchinsarcomascurrentstatusandfutureopportunities |